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vivo or in vitro. Pnt2258 is currently undergoing clinical 
testing to evaluate safety and antitumor activity in patients 
with recurrent or refractory non-Hodgkin’s lymphoma and 
additional studies are planned.
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Introduction
BCl-2, a member of the antiapoptotic protein family, plays 
a key and central role in preventing cell death, a defining 
characteristic of malignant cells [1]. BCl-2 confers an 
antideath phenotype and its overexpression contributes to 
the genesis of hematopoietic and lymphatic cancers [2–6]. 
aberrant BCl-2 expression is driven by t(14;18) chromo-
somal rearrangement of the BCl-2 gene in many follicular 
(Fl) and diffuse large B cell (DlBCl) lymphomas [3–6]. 
In chronic lymphocytic leukemia, impaired degradation 
of BCl-2 mrna is linked to nucleolin and/or microrna 
Abstract Pnt100 is a 24-base, chemically unmodified 
Dna oligonucleotide sequence that is complementary to 
a region upstream of the BCl-2 gene. exposure of tumor 
cells to Pnt100 results in suppression of proliferation and 
cell death by a process called Dna interference. Pnt2258 
is Pnt100 that is encapsulated in protective amphoteric 
liposomes developed to efficiently encapsulate the Pnt100 
oligonucleotide, provide enhanced serum stability, opti-
mized pharmacokinetic properties and antitumor activity of 
the nanoparticle both in vivo and in vitro. Pnt2258 dem-
onstrates broad antitumor activity against BCl-2-driven 
WSU-DlCl2 lymphoma, highly resistant a375 melanoma, 
PC-3 prostate, and Daudi-Burkitt’s lymphoma xenografts. 
the sequence specificity of Pnt100 was demonstrated 
against three control sequences (scrambled, mismatched, 
and reverse complement) all encapsulated in a lipid for-
mulation with identical particle characteristics, and control 
sequences did not demonstrate antiproliferative activity in 
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expression, resulting in continuous production of BCl-2 
protein and the subsequent survival of leukemic cells [7, 
8]. In cancers of the breast, skin, prostate, sarcomas, and 
lung, BCl-2 is implicated in the development of chemo-
resistance [9]. given its biological importance, BCl-2 is 
a desirable target for therapeutic development. numerous 
approaches have been reported to block or modulate the 
production of BCl-2 at the Dna level (e.g., retinoids and 
histone deacetylase inhibitors), at the rna level (targeted 
antisense oligonucleotides, sirna or mirna), or the pro-
tein level (e.g., pan inhibitors of BH3 family members of 
BCl-2, or recently the specific BCl-2 inhibitor, aBt-199) 
reviewed in [10].
there is an emerging understanding that Cpg islands 
surround mammalian cell promoter regions and that these 
non-methylated regions contribute to gene regulation [11, 
12]. the recognition that these genomic regions are Dnase 
I-hypersensitive enabled the discovery of cis-regulatory 
elements that act as transcription factors, enhancers, silenc-
ers, repressors, or control regions, which regulate gene 
expression [13–15]. additionally, higher-order secondary 
structures (quadruplexes, cruciforms, or I-motifs) that sur-
round the promoter regions of oncogenes may also serve as 
cis-regulatory domains to modulate transcription [16, 17]. 
It has been demonstrated that exposing cells to short Dna 
sequences containing these motifs reduced mrna and pro-
tein levels [18, 19]. Others have recognized the importance 
of regulatory regions specific for BCl-2 [20–23]. Young 
and Korsmeyer demonstrated that a series of 20 base dele-
tions between the P1 and P2 promoter of BCl-2 decreased 
transcription. Miyashita et al. reported that p53-dependent 
regions upstream of the BCl-2 gene act as negative regu-
latory elements, and Duan et al. showed long-range regu-
latory effects on BCl-2 transcription by enhancers in the 
IgH 3’ region. the observations support the hypotheses that 
these regulatory regions may be favorable therapeutic tar-
gets for hybridization due to the accessible chromatin state 
during oncogene up-regulation and transcription.
We describe a novel approach to blocking transcription 
termed Dna interference (Dnai®). Dnai therapeutic can-
didates are a new class of nucleic acid-based drugs. they 
are single-stranded sequences of unmodified phosphodies-
ter Dna having lengths of 20–34 bases. these sequences 
are designed to be complementary to non-coding, non-
transcribed regions of genomic Dna upstream of gene 
transcription start sites. the hybridization of the Dna-
interfering oligonucleotide to its targeted region results in 
gene modulation with phenotypic changes and a modula-
tion of mrna and protein levels. While Dnai against 
BCl-2 is described in this paper, Dnai oligonucleotides 
may be designed to also target other regions of the genome 
to modulate genes. We describe here the development of 
Pnt2258, containing Pnt100, a 24-base single-stranded 
Dna oligonucleotide specific to BCl-2 encapsulated in 
amphoteric liposomes. the liposomes protect the oligo-
nucleotides from nuclease degradation, facilitate cellular 
uptake, and enable endosomal escape to the nucleus, where 
the biological effects of the oligonucleotides occur [24–
26]. Pnt2258 is currently undergoing clinical development 
against BCl-2-driven malignancies [27].
Materials and methods
Pnt100 and control Dnai oligonucleotides
Oligonucleotides were produced by multi-step solid-phase 
organic synthesis involving on-column cleavage from solid 
support, base de-protection, followed by ion exchange 
(IeX) purification, ultrafiltration/diafiltration, concentra-
tion, and freeze-drying. the Pnt100 and controls include: 
Pnt100, 5′-CaCgCaCgCgCatCCCCgCCCgtg-3′; 
methylated Pnt100, 5′-CaXgCaXgXgCatCCCXgCC 
Xgtg-3′, where X represents a methylated cytosine base; 
scrambled control, 5′-CggCgtgCaCCCCaCCCaCgCC 
gt-3′; reverse complement control, 5′-CaCgggCgggga 
tgCgCgtgCgtg-3′, which is the reverse sequence of 
Pnt100 and is 100 % homologous with the coding strand; 
mismatched control, 5′-CaCgCaCgCgCatCCttgCCC 
gtg-3′ or 5′-CaCgCaCgCgCatCCttgCCCatg-3′; 
randomer, 5′-nnnnnnnnnnnnnnnnnnnnnnnn-3′, 
where n represents a wobble; Pnt100cy 5′-CaCgCgCgCg 
CatCCCCgCCCgtg-3′. Oligonucleotides were pur-
chased from trilink, Dow, Sigma, or nIttO DenKO 
avecia.
lipids and transfection agents
neoPhectin at containing the cationic cardiolipin 1, 
3-Bis-(1,2-bis-tetradecyloxy-propyl-3-dimethylethoxyam-
moniumbromide)-propane 2-ol was purchased from neoP-
harm (Waukegan, Il). 1-Palmitoyl-2-oleoyl-sn-glycero-3 
phosphocholine (POPC) and 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPe) were purchased from 
lipoid gmbH or avanti Polar lipids. Cholesteryl hemi-
succinate (CHeMS) and cholesteryl-4-[[2-(4-morpholinyl)
ethyl]amino]-4-oxobutanoate (MOCHOl) were produced 
by Merck & Cie (Shaffhuasen, Switzerland).
Preparation of encapsulated oligonucleotides and Pnt2258
During preliminary screening, oligonucleotides were 
encapsulated in a variety of liposome compositions, includ-
ing the cationic neoPhectin at system and into various 
amphoteric liposomes denoted as SMartICleS® (from 
novosom ag, now Marina Biotech). While neoPhectin 
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spontaneously forms liposomes upon mixing with oligo-
nucleotides, the other lipids that generate the amphoteric 
liposomes were mixed in ethanol and combined with an 
acidified (pH 4) aqueous solution of each oligonucleotide 
tested. the mixing process with the latter results in encap-
sulation in a 30 % ethanol suspension followed by dilution 
in an excess of phosphate-buffered saline with simultane-
ous neutralization to pH 7.5 [26, 28, 29]. For Pnt2258, a 
cross-flow injection technique was utilized to enable con-
tinuous mixing of the lipid ethanolic solution with aqueous 
Pnt100 to encapsulate Pnt100 in liposomes followed by 
an immediate pH shift to neutralize the mixture. ethanol 
was removed by dialysis or diafiltration to exchange saline 
with sucrose (phosphate-buffered sucrose), followed by 
sterile filtration and filling into glass vials.
Characterization of the physicochemical properties 
of formulation solutions and dosing solutions 
of oligonucleotides
OD260-derived concentrations, representing total oligonu-
cleotide content, were used to compare encapsulated oli-
gonucleotide dosing solutions used for animal studies with 
Pnt100, control oligonucleotides, and prototype Pnt2258 
formulations. Standard curves with each oligonucleotide 
were used along with spectral scans to confirm the OD260 
contribution resulted from the oligonucleotides and not the 
liposome/lipid nanoparticles. the percent unencapsulated 
oligonucleotide was determined by OD260 following ultra-
filtration using Centrisart 100 K cutoff membranes. Where 
indicated, the Pnt2258 concentrations were reported as 
Pnt100 content after correcting for purity as determined by 
ion exchange (IeX) chromatography. reverse-phase HPlC 
was used to quantify lipids in the nanoparticles. Particle 
diameters and zeta potentials were determined by dynamic 
light scattering using a Malvern nano ZS (Malvern, Pa).
Cell culture and treatment with Dnai
Cell lines were maintained in suspension or monolayer cul-
tures in media supplemented with 10 % fetal bovine serum 
(FBS). Breast (MDa-MB-231, Bt-474, and t47D), mela-
noma (a375 and M14), prostate PC-3, lymphoma (Daudi-
Burkitt’s, SU-DHl-6, and Pfeiffer), and mouse mammary 
nMuMg lines were purchased from atCC®. WSU-DlCl2 
and WSU-FSCCl lines were purchased from DSMZ gmbH 
(germany) or provided by ramzi Mohammad of Wayne 
State University. the cell lines were authenticated by the 
providers and were maintained under the recommended 
conditions for propagation and experimental use.
Unless otherwise noted, cell exposure studies utilized 
methylated oligonucleotides without formulation. For 
adherent lines, cells were seeded in 6- or 24- well plates or 
t-25 flasks (Corning life Sciences) at 2.0 × 105 cells per 
flask in 5 ml media. One day after passage, the medium 
was replaced with fresh media containing the test oligonu-
cleotides. Cultures were incubated at 37 °C in a humidified 
atmosphere of 5 % CO2. Cells were washed with 1× PBS 
and incubated with 0.25–1 % trypsin and 0.02 % eDta 
to disperse the cells. the number of living and dead cells 
was assessed following 0.1 % trypan blue exposure, with 
the percentage of inhibition reported as a percent of live 
cells present in saline-treated controls. the effects of treat-
ment on proliferation were assessed using Mtt assay with 
2,500 cells per well seeded in 96-well plates. Suspended 
cells were grown in 24-well plates and treated as described 
above. For PC-3 exposure studies, oligonucleotides were 
formulated with neoPhectin. typically, cells were exposed 
for 30 min or 6 h, washed, then the effects of treatment 
on proliferation were assess by Celltiter-glo® (Promega) 
48 h post-treatment or BCl-2 and gaPDH expression was 
measured by qPCr.
Pharmacokinetics, pharmacology, tissue distribution, 
and xenograft studies
Pharmacokinetic studies and xenograft animal studies
Pnt2258 and its prototypes were evaluated as single 
agents or in combination in four different human tumor 
xenograft model systems. two of the models were non-
Hodgkin’s lymphoma models (WSU-DlCl2 (a diffuse 
large B-cell) and Daudi-Burkitt’s). the other xenograft 
models included a375 melanoma and the PC-3 hormone 
refractory prostate carcinoma. For WSU-DlCl2, female 
ICr SCID mice (taconic) or female C.B-17 SCID mice 
were implanted subcutaneously with donor WSU-DlCl2 
xenograft fragments in their flanks. a parallel set of WSU-
DlCl2 xenograft mice were also used for tissue distribu-
tion studies. For Daudi-Burkitt’s, female C.B-17 SCID 
mice were implanted subcutaneously with 1 × 107 Daudi 
cells in their flanks. a parallel set of Daudi-Burkitt’s xeno-
graft mice were also used for pharmacokinetic and tissue 
distribution studies. For a375, female nu/nu mice were 
implanted subcutaneously in the flank with 1 mm3 frag-
ments. For PC-3, male SCID/nCr mice were subcutane-
ously implanted with 5 × 106 PC-3 cells. all xenograft 
tumor models were conducted through contract or research 
collaborations at MPI research (PC-3), South texas accel-
erated research therapeutics (a375 and WSU-DlCl2), 
Piedmont research (Daudi and a375), Karmanos Cancer 
Center (WSU-DlCl2), and Van andel research Institute 
(PC-3). BalB/C mice were purchased from Charles river 
labs and used for pharmacokinetic studies. test samples 
were provided in a blinded manner. all protocols and pro-
cedures employed in this work were approved by each 
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testing centers’ Institutional animal Care and Use Commit-
tee (IaCUC).
Animal monitoring, tumor measurement, and data 
calculation
Upon attaining tumor volumes of 100–200 mm3, animals 
were randomized into treatment groups. thereafter, clini-
cal signs, tumor measurements, and body weights were 
recorded 3–5 times per week. tumor volume was cal-
culated using the formula (l × w2)/2, where l and w are 
the length and width of the tumor, respectively. animals 
were euthanized when tumor sizes reached 1,000 mm3, 
2,000 mm3 or at approximately 60 days depending on the 
research organizations’ approved protocols. efficacy end-
points, including time to tumor endpoint, tumor growth 
delay, and net log10 cell kill, were calculated as follows 
using previously described methods [30]. gross cell kill 
was calculated using the following formula: [t-C (days)]/
(3.32 * td), where t-C is the tumor growth delay and td is 
the tumor volume doubling time (days). Individual tumor 
volumes which decreased to <50 % of their volumes at 
treatment initiation for three consecutive measurements 
were considered partial regressions (Pr). Individual tumor 
volumes that were not measurable for three consecutive 
measurements were considered complete regressions (Cr). 
Complete regressions persisting until the end of the study 
were considered tumor-free survivors (tFS). Data and 
statistics were analyzed using Prism 5.0 (graphPad; San 
Diego, Ca) and Microsoft excel.
Plasma measurement of PNT2258 by hybridization–
ligation and plasma immune markers
Whole blood was collected in K2eDta-coated tubes, 
placed on ice, centrifuged to obtain plasma and stored at 
−80 °C until analyses. Samples were treated with 10 % 
(v/v) tween-20 detergent and heated to 90 °C to liber-
ate Pnt100 from Pnt2258 then diluted fourfold with a 
template probe (complementary and specific to the entire 
sequence of Pnt100) labeled with biotin on its 3′-end and 
a 9-mer overhang to the opposing end. the solution was 
incubated at 37 °C for 1 h in neutravidin-coated plates, 
prior to the addition of a mixture containing a digoxigenin-
label signal probe which ligates the 3′ terminus of Pnt100 
with the 5′end of the ligation probe. Unbound ligation 
probe was washed away prior to antibody (targeting digoxi-
genin) addition and conjugation to alkaline phosphatase. 
attoPhos® substrate was added and the reaction terminated 
with eDta solution prior to fluorescent signal measure-
ment (excitation: 435 nm; emission: 555 nm). the lower 
limit of quantitation (llOQ) was 3 ng/ml using Pnt2258 
as a standard. Multiplex immunoassays of mouse plasma 
obtained from WSU-DlCl2-tumored animals 8 h post-
Pnt2258 dose were assayed in triplicate per the affym-
etrix Procarta Mouse 37-plex kit protocols (Fremont, Ca) 
and visualized using a luminex 100 IS System (luminex 
Corporation, austin, tX). analyte concentrations were cal-
culated from the standard curves using Bio-Plex Manager 
4.1.1 (Bio-rad laboratories, Hercules, Ca). Statistical 
analysis was done using Student t statistic; P values <0.05 
were considered significant.
Pharmacodynamic sampling of tumors and PNT2258 
tissue levels
tumors and organs were collected, snap frozen, weighed, 
and stored until analyses. tissue levels of Pnt2258 were 
assessed by two independent labs, Charles river labs and 
Helix Diagnostics, using the hybridization–ligation assay 
described above for plasma analyses (llOQ: 50 μg/g of 
tissue) or by capillary gel electrophoretic detection (llOQ: 
5 ng/g of tissue). Pnt2258 levels in xenograft tumors 
were measured through direct hybridization with capture 
and extender probes that recognize only Pnt100 amidst 
the total rna extract (llOQ 300,000 copies of Pnt100). 
tumor homogenates were prepared by pulverizing tumors 
under liquid nitrogen, followed by homogenization in 900 
μl of homogenizing solution (affymetrix) supplemented 
with 9 μl of proteinase K (50 mg/ml). the homogenates 
were incubated at 65 °C for 30 min, then clarified by cen-
trifugation, and stored at −70 °C until analyses. tumors 
excised from animals treated with Pnt100 formulated 
with neoPhectin, Pnt100r formulated with neoPhectin, 
neoPhectin alone, or sucrose (vehicle control) were pooled 
into groups, dissected mechanically into single cell suspen-
sions, and subjected to protein analysis by Western blot 
using antibodies (Santa Cruz Biotechnology) along with 
total protein quantitation by BCa assay (Pierce).
Results
Demonstration of antiproliferative and cytotoxic effects 
of Dnai oligonucleotides and selection of Pnt100
Oligonucleotide sequences targeted along the 5′ region 
upstream of the BCl-2 atg start site were synthesized and 
tested for antiproliferative activity against breast and mel-
anoma cell lines. the oligonucleotides ranged from 20 to 
26 bases in length, contained 61–100 % Cg content, and 
mapped within the region translocated during the t(14;18) 
rearrangement. the oligonucleotides were methylated at 
the cytosine bases when used in cell exposure studies. the 
sequences were identical to the non-template strand and 
100 % complementary to the template strand of genomic 
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Dna. Of the oligonucleotides tested, a 24-base sequence of 
5′-CaXgCaXgXgCatCCCXgCCXgtg-3′ showed the 
broadest antiproliferative effects against a panel of breast 
(67–76 % inhibition) and melanoma (42–65 %) cell lines 
(see Supplemental Figure S1a). this oligonucleotide also 
showed robust and time-dependent cytotoxic effects in 
WSU-FSCCl (see Supplemental Figure S1B), a fast grow-
ing BCl-2 and CMYC-driven non-Hodgkin’s follicular 
lymphoma cell line characterized by the BCl-2 t(14;18)
(q32;q21) and CMYC t(8;11)(q24;q21) rearrangements 
[31]. Furthermore, Bl2 (which represents methylated 
Pnt100) and Bl7 were counterscreened against an immor-
talized normal mouse mammary gland cell line (nMuMg, 
see Supplemental Figure S1C). Bl2 (mePnt100) did not 
result in cytotoxicity at either 24 or 96 h post-exposure, 
whereas Bl7 showed significant cytotoxicity at 96 h post-
exposure. the lack of cytotoxicity in Bl2 suggests speci-
ficity for the human sequence. this 24-base sequence was 
nominated as a lead BCl-2 therapeutic candidate and fur-
ther tested for sequence specificity.
In vitro sequence specificity testing of Pnt100
to determine whether methylation was necessary for anti-
proliferative and cytotoxic effects, mePnt100 and unmeth-
ylated Pnt100 were combined with a transfection agent, 
neoPhectin at, and the cytotoxic effects against PC-3 cells 
were tested (see Fig. 1a). the results showed equal activ-
ity between mePnt100 and Pnt100, with approximately a 
50 % reduction of cell proliferation post-exposure. Further-
more, the activity of Pnt100 was compared to randomer, 
mismatched, and a reverse control of Pnt100 (Pnt100r) 
oligonucleotide controls. With the exception of the scram-
bled control, all sequences tested had identical 3’termini to 
control for any non-specific toxicity that has been reported 
due to the release of terminal bases [32]. Data show mini-
mal antiproliferative effect of these oligonucleotides when 
compared to saline control (see Fig. 1a), with Pnt100 or 
mePnt100 having the greatest effect. the activity was not 
influenced by the presence of 5-azacytidine, an inhibitor 
of Dna methyltransferase activity (Fig. 1a, right panel), 
indicating that the effect was not methylation dependent 
[33]. Further, BCl-2 expression following exposure with 
Pnt100 was compared to the scrambled control (Fig. 1b).
to develop Pnt100 as an intravenous drug candidate, 
liposomes were chosen to protect the unmodified oligonu-
cleotide, enhance its pharmacokinetic profile, and facili-
tate cellular delivery. Initially, neoPhectin was evaluated. 
the lipid components in neoPhectin are similar to lera-
faOn, a liposome-encapsulated antiraf antisense oligonu-
cleotide developed by neoPharm [34]. Pnt100 formulated 
with neoPhectin demonstrated antitumor activity against 
WSU-DlCl2 xenografts and reduced BCl-2 expression 
in excised tumors when assessed 26 days post-treatment 
(Fig. 1c) when compared to liposome controls (neoPhectin 
alone) or the reverse sequence of Pnt100 formulated with 
neoPhectin (neoPhectin Pnt100r). Pnt100 formulated 
with neoPhectin (neoPhectin Pnt100), however, did not 
demonstrate consistent stability when exposed to serum or 
physicochemical characteristics suitable for development 
as an oncology therapeutic. therefore, candidates for a new 
delivery system were screened.
evaluation of amphoteric liposomes and optimization
the SMartICleS® platform represents a series of 
liposomes having amphoteric properties (i.e., pH-depend-
ent prevalence of either acidic or basic groups) that may 
be modulated across physiological pH ranges. this plat-
form showed promising serum stability and proven tissue 
delivery with broad cellular localization, including nuclear 
delivery [26]. a number of lipid compositions including 
pH-sensitive cationic or anionic, fusogenic, and bilayer/
stabilizing lipids were tested. Formulations that met crite-
ria of >50 % encapsulation, <15 % serum release, <200 nm 
particle size, and <0.2 poly-dispersity underwent further 
testing in xenograft models. encapsulated Pnt100 and 
Pnt100r were tested for antitumor activity against PC-3 
xenografts as single agents and in combination with doc-
etaxel (Fig. 2a). as single agents, all formulations contain-
ing Pnt100 showed activity (labeled as 1, 2, or 3) with 
formulation 1 and 2 showing greater activity than 3, but 
equivalent tumor growth delay. less activity was observed 
with formulations containing Pnt100r (labeled as 1r, 2r, 
or 3r). Formulation 1 was chosen because (1) it showed 
good single-agent activity and an additive effect with 
encapsulated Pnt100 when combined with docetaxel and 
(2) the liposome formulation showed the least antitumor 
activity with Pnt00r as a single agent or in combination 
with docetaxel. therefore, based on the results from this 
activity screen and the physicochemical characterizations, a 
composition of POPC, DOPe, CHeMS, and MOCHOl at 
molar ratios of 6:24:23:47 was chosen for Pnt2258.
Due to the robust and consistent single-agent activ-
ity observed, the drug product characteristics of Pnt2258 
were optimized in vivo against WSU-DlCl2 tumor xen-
ografts. a broad dose range was tested (Fig. 2b). How-
ever, as seen, at doses of ~10 mg/kg, increasing the dose 
further did not produce additional antitumor activity, and 
increasing the dose even further produced frank toxic-
ity in the experimental animals. these data suggested that 
the dose–response curve for Pnt2258 is relatively flat in 
mice over the effective dose range and is consistent with 
dose-dependent pharmacokinetics and therapeutic efficacy 
often seen with liposome-delivered therapeutics once satu-
ration or clearance blockade is achieved [36]. the effects 
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of Pnt100-to-lipid ratio, particle size, size distribution, 
and freezing on antitumor activity were testing iteratively 
in WSU-DlCl2-tumored mice and these are summarized 
in table 1. Pre-optimization formulations administered IV 
for five consecutive days at a 10 mg/kg Pnt100 equivalent 
dose (q5d) resulted in a tgD of 0–13 days and net log10 
cell kills of 0–0.5 across the doses tested. net kill is the 
change in tumor burden (logs) over the treatment period 
and enables the quantitative comparison of efficacy across 
experimental protocols by normalizing the efficacy data for 
treatment regimens of varied duration and differences in 
tumor growth rates between experiments or models. Posi-
tive values indicate a reduction of tumor burden occurred 
at the end of therapy relative to the pre-treatment burden. 
Post-optimization formulations (designated as Pnt2255 
or Pnt2256) resulted in a tgD of 23–36 days, net log10 
Fig. 1  effect of Pnt100 or controls formulated with neoPhectin on 
cell proliferation, BCl-2 expression, and antitumor activity. a Left 
panel PC-3 prostate cancer cells were exposed to 10 μM Pnt100 
(triplicate per group), methylated Pnt100, and controls. after 6 h 
of exposure, cells were washed and allowed to equilibrate and ana-
lyzed 48 h post-exposure by Cell titer-glo assay. *P < 0.001 versus 
control, ♦P < 0.001 versus scrambled, mismatched, randomer, and 
reverse control (Pnt100r). a Right panel in a separate experiment, 
PC-3 prostate cancer cells were exposed to 5 μM 5′-azacytidine in 
combination with 10 μM Pnt100, randomer or scrambled control. 
after 72 h of exposure, cells were analyzed for viability by Cell 
titer-glo assay. P < 0.0001 versus scrambled or randomer control. 
b BCl-2 levels in PC-3 prostate cancer cells exposed to Pnt100 
and the scrambled control (10 μM). after 6 h of exposure, BCl-2 
and gaPDH rna expressions were analyzed via qPCr. *P < 0.05 
versus scrambled control. c Mean tumor size in animals following 
intravenous administration (IV, via tail vein) of 10 mg/kg Pnt100 
(neoPhectin Pnt100), reverse control (neoPhectin Pnt100r) or 
the vehicle controls (saline or neoPhectin liposomes). WSU-DlCl2 
tumor xenografts were implanted subcutaneously into animals and 
allowed to grow to an average of 100 mm3 size prior to treatment 
with five daily doses. animals (n = 8 for all groups) were killed 
26 days post-dosing, mean tumor weights measured, and BCl-2 pro-
tein levels were analyzed using protein immunoblots. *P < 0.05 ver-
sus Saline control, neoPhectin liposome control, and neoPhectin 
Pnt100r
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cell kills of 1–2, and a proportionate increase in complete 
responses and tumor-free survivors (table 1). Of note, tar-
geting average particle diameters of ~130 nm and changing 
Pnt100-to-lipid ratios to 1:25 from 1:50 improved activity. 
Process refinements (mixing conditions, extrusion to refine 
particle size, and polydispersity) were applied, and these 
prototype formulations were tested at doses of 10 mg/kg to 
define the physicochemical characteristics of encapsulated 
Pnt100. the efficacy of frozen versus refrigerated formu-
lations of Pnt2258 alone or in combination with rituximab 
showed that freezing the formulation demonstrated at least 
equivalent activity and equivalent physicochemical charac-
teristics upon thawing when compared to the refrigerated 
formulation, indicating that freezing did not affect activity 
(table 1). therefore, freezing was implemented as the final 
step during manufacturing to enhance shelf life. the result-
ing nanoparticles with a diameter of approximately 130 nm 
encapsulating Pnt100 at an oligonucleotide-to-lipid ratio 
of 1:25 (w/v) was designated as Pnt2258.
Pharmacokinetics, tissue distribution, and immune 
evaluation of Pnt2258
Pnt100 and Pnt2258 were shown to be stable in whole 
blood for at least 24 h at 37 °C. Detergent addition and heat-
ing samples at 90 °C were required prior to being able to 
detect Pnt100 in Pnt2258 by the hybridization–ligation 
method. Further, no degradation of spiked Pnt100 or 
Pnt2258 was observed with long-term storage at −80 °C 
(>200 days). In effect, no unencapsulated Pnt100 is 
detected in plasma obtained post-intravenous administra-
tion. Pretreatment of plasma or tissue samples post-IV 
administration to release Pnt100 from Pnt2258 suggests 
that the nanoparticle remains intact. Similar findings were 
noted with Pnt100, Pnt2258, or Pnt2258cy (encapsu-
lated cynomolgus monkey-specific sequence of Pnt100) 
visualized by SYBr green post-24 h exposure in whole 
blood (nanotechnology Characterization laboratory (nCl), 
unpublished results). Dose-proportional plasma exposure in 
BalB/c mice treated with 3, 10, or 20 mg/kg Pnt2258 was 
seen with area under the curve values of 22,377, 219,986 
or 1,588,000 ng h/ml and Cmax values of 16,585, 37,250 or 
151,088 ng/ml, respectively. Half-lives ranged from 2.5 to 
9 h. Plasma concentrations for each of the three doses are 
shown in Fig. 3a. the pharmacokinetic profiles of Pnt2258 
(20 mg/kg) as a single agent (Cmax 148,331 ng/ml) or in 
combination with rituximab (Cmax 120,256 ng/ml) in SCID 
mice with Daudi xenografts were similar to the BalB/c 
profile, demonstrating a consistent pharmacokinetic profile 
between naïve and xenografted animals.
Fig. 2  antitumor activity against xenograft tumors of several for-
mulations of Pnt100 or Pnt100r encapsulated in SMartICleS 
(amphoteric liposomes) and the dose response of Pnt100 in the 
chosen formulation. a SCID/nCr mice were implanted with PC-3 
cells and treated with vehicle (saline) control, Pnt100r or Pnt100 
encapsulated in three different lipid compositions as a single agent or 
in combination with docetaxel. Pnt100, Pnt100r, and the vehicle 
control were administered IV at 10 mg/kg daily for 5 days. Docetaxel 
was dosed at 2 and 5 mg/kg on day 2 and 5, respectively. Bars repre-
sent the median tumor growth delay (n = 5 for all groups). Various 
liposome formulations with Pnt100 are represented as numbers (i.e., 
1, 2, and 3), while the corresponding formulations with Pnt100r are 
designed with “r” (i.e., 1r, 2r, and 3r). Formulation 1 is Pnt2258. 
b Dose response of prototype Pnt2258 (Pnt100 encapsulated in 
lipid composition chosen for Pnt2258, pre-optimization). SCID 
mice were implanted with WSU-DlCl2 cells and administered IV 
with saline (vehicle control) or prototype Pnt2258 at doses ranging 
from 0.3 to 30 mg/kg (based on OD260 total oligonucleotide con-
tent). Mean tumor volumes following treatment (n = 7 per group) are 
shown. *P < 0.05 versus vehicle control and prototype Pnt2258 at 
0.3 and 3 mg/kg. Improvements made from pre-optimization to post-
optimization resulted in an increase in tumor growth delay from 9 to 
21 days and an increase in net cell kill from 0.2 to 1.1 using the same 
dose (10 mg/kg) and schedule (QDx5)
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the tissue distribution of Pnt2258 levels measured 
after homogenization of tissues and quantified using cap-
illary gel electrophoresis to detect the hybridization of 
Pnt100 with its specific fluorescent probe is shown in 
Fig. 3b. a consistent with pharmacokinetic clearance, at 8 h 
post-dose the liver (~10 %), spleen (~12 %), and blood rep-
resented approximately 40–50 % of the injected dose with 
the remainder across a broad tissue distribution including 
uptake in tumors of WSU-DlCl2 tumor-bearing mice. the 
uptake of Pnt2258 into Hela cells is shown in Fig. 3c. 
Hela cells were used to demonstrate Pnt2258 uptake 
because these cells are relatively resistant to Pnt2258-
induced cytotoxicity, thereby allowing a time course of 
uptake to be conducted. Based on the qualitative formula-
tion screen of antitumor activity, physicochemical results, 
ease of preparation, and in vivo tumor cell localization, the 
lipid composition to encapsulate Pnt100 was selected and 
further optimized.
the sequence specificity of Pnt100’s antitumor activity 
in amphoteric liposomes was reconfirmed by demonstrat-
ing antitumor activity of Pnt2258, but not control oligo-
nucleotides (Fig. 4a). Unmodified oligonucleotides, being 
natural structures, are quickly degraded and eliminated if 
not protected (e.g., within a liposomal formulation like 
Pnt2258) and are generally not toxic even at high doses. 
However, liposomal encapsulation alters the innocuous 
nature of an unmodified oligonucleotide and published 
reports suggest encapsulation enhances immunostimula-
tory properties especially in rodents. While Pnt100 con-
tains Cpg sequences, it does not contain known motifs that 
are immunostimulatory. therefore, to eliminate a concern 
that immune stimulation was driving Pnt100’s BCl-
2-targeted antitumor activity, a parallel set of xenografted 
animals were treated with either Pnt2258 or encapsulated 
Fig. 3  Pharmacokinetics, tissue distribution, and time course of 
cellular uptake of Pnt2258. a Pharmacokinetics of Pnt2258 in 
BalB/c or SCID Daudi-Burkitt’s-tumored mice measured in plasma 
by the hybridization–ligation assay. Pnt2258 was administered IV as 
a single dose at 3, 10, or 20 mg/kg (n = 3/group) in BalB/c mice 
(data shown in orange). Pnt2258 was administered as a single dose 
at 20 mg/kg as a single agent or in combination with a single dose 
of rituximab (20 mg/kg). N = 3 or 4 per group, data shown in blue. 
Both agents were administered IV within 5 min of each other. Blood 
was collected at 5, 15, 30 min, 1, 2, 4, 8, and 24 h and plasma was 
stored at −80 °C until analysis. b tissue distribution of Pnt2258 in 
WSU-DlCl2-tumored mice. nude mice were implanted with WSU-
DlCl2 cells and administered IV with 20 mg/kg Pnt2258. tissue 
samples were collected at 8 h after the initial treatment for analysis 
by gel capillary electrophoresis visualized by hybridization with a 
Pnt100-specific fluorescent probe. Blood was collected 8 h post-
dose and plasma was analyzed by the hybridization–ligation assay. c 
time course of Hela cell uptake of Cy5.5-labeled Pnt100 or encap-
sulated Cy5.5-labeled Pnt100 (representative of Pnt2258) moni-
tored by light phase and confocal microscopy
▸
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scrambled control, and plasma was obtained 24 h post-
dose and tested for immune marker modulation (Fig. 4b). 
Pnt2258 and the scrambled control produced similar 
immune responses in tumor-bearing immune-compromised 
mice. Markers indicative of innate immune stimulation 
(IFnγ, Il-6, Il-12p40, IP-10, ranteS) and nanoparticle 
recognition (MCP-1, MCP-3, g-CSF) were increased fol-
lowing dosing. these findings support a BCl-2-targeted 
antitumor effect as a result of treatment with Pnt2258 and 
rule out a non-specific immune response driving xenograft 
antitumor activity. additional studies exposing Pnt100, 
Pnt2258, encapsulated scrambled control, Pnt228cy, 
or empty liposomes to human PBMCs, and probing with 
a broad immunoplex panel demonstrate modest immune 
stimulation and are attributed to the recognition of the 
amphoteric liposome carrier (data not shown and unpub-
lished results, nCl Collaboration). the modulation of 
BCl-2 following incubation with Pnt2258 was confirmed 
in a SU-DHl-6 lymphoma cell line (Fig. 4c).
Dose schedule effects of pre-optimized Pnt2258 
on antitumor activity
three treatment schedules, daily for 5 days (QDx5), every 
other day with seven doses (Q2Dx7), and every third day 
with eight doses (Q3Dx8), at 10 mg/kg were evaluated 
Fig. 4  antitumor activity and plasma immune markers following the 
administration of Pnt100 or control oligonucleotides encapsulated 
in the lipid composition chosen for Pnt2258. a Mean tumor volume 
in SCID mice-bearing WSU-DlCl2 xenografts at 28 days post-
tumor implant following IV treatment (10 mg/kg for 5 consecutive 
days) with Pnt100, methylated Pnt100, scrambled, mismatched, 
or vehicle control (n = 8 for all groups). *P < 0.05 versus vehicle, 
scrambled, and mismatched controls. b Plasma immune markers in 
WSU-DlCl2-tumored animals following a single dose of Pnt2258 
(n = 5) or encapsulated scrambled (n = 5) control represented as a 
percent of control (saline-treated n = 5). Similar profiles and magni-
tude of response were seen with Pnt2258 and the scrambled control. 
the only significant difference in marker expression between the two 
treatment groups was in IFnγ (*P < 0.05). MCP-1, IFnγ, ranteS, 
Il12/Il23-p40, MCP-3, and g-CSF were all significantly differ-
ent in both treatment groups compared with the other 31 markers 
(♦P < 0.05). c SU-DHl6 lymphoma cells were exposed to Pnt2258 
at 2.5, 5, and 10 μM. after 72 h of exposure, the contents of triplicate 
wells were pooled for the BCl-2 protein by immunoblots. the bar 
graph above the blots represents the densitometric quantification of 
the BCl-2 protein normalized against actin protein levels
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against WSU-DlCl2 xenograft tumors (see Fig. 5). tumor 
growth delay (Fig. 5a) and net log10 tumor cell kill (net 
kill; Fig. 5b) as a secondary efficacy endpoint were used to 
compare the activity between treatments. the QDx5 treat-
ment schedule produced a tumor growth delay in excess 
of 31 days with a corresponding net kill of 1.7 logs, while 
the tumor growth delay values for the other two treatment 
schedules were less than 10 days and had negative net kill 
values, indicating tumor progression. these data suggested 
the QDx5 treatment schedule was superior and prompted 
the use of the daily, 5 days treatment schedule in future 
studies in xenograft studies. the maximum-tolerated dose 
(MtD) of Pnt2258 prototypes was generally 20–30 mg/kg 
and was xenograft model independent. the MtD is defined 
at the dose that produces less than 20 % weight loss and is 
less than or equal to the lD10 in the experimental animals. 
Weight loss induced by Pnt2258 was dose responsive, but 
never exceeded 20 %. Further, in other testing paradigms, 
additional treatment cycles were added so that the experi-
mental animals received Pnt2258 5 days per week for three 
consecutive weeks. no dose-limiting toxicities, assessed by 
body weight changes, were noted between groups.
Pnt2258 activity across tumor xenograft models
the activity of Pnt2258 was tested as a single agent or in 
combination with docetaxel or rituximab across four xeno-
graft models, WSU-DlCl2 lymphoma, Daudi-Burkitt’s 
lymphoma, PC-3 prostate, and a375 melanoma and are 
summarized in Fig. 6a and Supplemental table 1. WSU-
DlCl2 xenografts are representative of a lymphoma cell 
line harboring the t(14;18) rearrangement with constitutive 
nF-κB activation driving not only proliferation, but also 
increased BCl-2 transcription. Daudi-Burkitt’s xenografts 
harbor a (t8;14) rearrangement and is primarily a CMYC-
driven lymphoma subtype. PC-3 xenografts represent a 
radioresistant model, attributed to increased BCl-2 tran-
scription [35]. a375 is a human-derived melanoma cell 
line harboring a BraF mutation due to the substitution 
of valine for glutamic acid at codon 600, termed V600e 
resulting in constitutive activation, aggressive proliferation, 
and high BCl-2 expression. the tumor growth curves for 
control (saline), Pnt2258, docetaxel, or rituximab as single 
agents or combination treatments are presented in the left 
panels, with overall survival shown in the corresponding 
right panels. generally, weight loss induced by Pnt2258 
was dose dependent, but average treated body weights did 
not decrease below 20 % of baseline at any dose as a single 
agent or in combination with cytotoxic agents.
to compare the activity across models, the data are also 
represented as gross cell kill (Fig. 6b). Models are repre-
sented from left to right based on the single-agent activity 
of Pnt2258 (leftmost bar of each set), and interestingly, an 
alignment with literature reported BCl-2 protein expres-
sion [1, 37, 38]. In some models, there was significant 
positive interaction between Pnt2258 and standard agents 
(Daudi-Burkitt’s and a375). In the PC-3 and DlCl2 mod-
els, the interaction was less pronounced. the combination 
agents were administered at maximum-tolerated doses 
reported in the literature for each model and based on the 
testing facilities’ historically experiences. this dosing para-
digm, instead of using suboptimal combination doses, may 
account for the lack of synergistic or additive effect in the 
DlCl2 model because the combination agent was so effec-
tive. this is supported in other studies (not shown), where 
synergistic activity of Pnt2258 with docetaxel and rituxi-
mab was observed when these agents were used at sub-
optimal doses. the robust antitumor activity provided the 
rationale to move Pnt2258 further into toxicology evalua-
tion and subsequent clinical development.
Fig. 5  the effect of dose schedule on antitumor activity. a tumor 
growth delay in C.B-17 SCID mice-bearing WSU-DlCl2 xenografts 
following administration of 10 mg/kg Pnt2258 at the following dose 
schedules: five IV daily doses (QDx5), 8 IV doses given every third 
day (Q3Dx8), and 7 IV doses given every other day (Q2Dx7) (n = 7 
for all groups). b net log10 cell kill calculated for each dose schedule. 
a positive net log10 cell kill indicates a decrease, while a negative net 
log10 cell kill indicates an increase, in the tumor cell population at the 
end of treatment compared with the beginning of treatment
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Fig. 6  antitumor effect and 
percent survival of animals 
treated with Pnt2258 or com-
bination agent as single agents 
or in combination across four 
xenograft models. a Pnt2258 
or combination agent was tested 
against PC-3 (prostate, n = 10/
group), Daudi-Burkitt’s (lym-
phoma, n = 10/group), a375 
(melanoma, n = 10/group), 
and WSU-DlCl2 (lymphoma, 
n = 7/group) alone or in com-
bination. Symbols on the x-axis 
represent days of dosing for 
each treatment; the same sched-
ules were used in combination. 
the numbers in parentheses 
after each compound represent 
the dose (mg/kg) administered. 
all treatments were admin-
istered IV. In the PC-3 study, 
docetaxel was administered at 
10 mg/kg for the initial dose 
and then at 5 mg/kg for the 
subsequent dose. b gross cell 
kill (log10) across all four xeno-
graft models. numbers above 
thebars represent the tumor-free 
survivors per total animals in 
the treatment group. the lack of 
values above a bar indicates that 
there were no tumor-free survi-
vors for that treatment group
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Discussion
Oligonucleotide candidates modulating gene expression 
may be targeted at the level of either rna or genomic 
Dna. approaches to modulate genomic Dna include tri-
plex, quadruplex oligonucleotides, methylated forms of 
Dna or rna, or mismatched or single-base modifications 
of the Dna or rna oligonucleotides. these methodolo-
gies hybridize to transcription start sites to interfere with 
transcription, cause Dna cleavage, homologous recombi-
nation or act to stimulate inherent Dna repair mechanisms 
to correct the mismatches triggered by the hybrid double-
stranded Dna/Dna or chimeric rna/Dna interactions 
[38, 39]. to our knowledge, none of these Dna-targeted 
approaches have progressed into the clinic. In contrast, 
single- or double-stranded rna-targeted oligonucleo-
tide approaches have progressed to the point of providing 
clinical success reviewed in [40] and [41]. these include 
antisense or sirna that cause mrna cleavage and disrup-
tion of the rna translational machinery, rna modulation 
agents that correct gene defects by exon skipping, or micro-
rna mirs and antimirs agents that regulate the expres-
sion of multiple pathways by replacing absent sequences 
or antagonizing sequences, respectively. a common fea-
ture among these approaches is the use of chemical modi-
fications (e.g., phosphothioate, 2’-modified nucleic acids 
including MOe modifications and cet, conformationally 
restricted nucleic acids bases including lna and inverted 
bases) to enhance activity, pharmacokinetics, and pharma-
codynamics [reviewed in [42] ]. In addition, in some cases, 
the active rna sequences are not 100 % complementary to 
their target mrna.
the 24-base BCl-2-targeted oligonucleotide, Pnt100 
represents a new class of Dna therapeutics being devel-
oped that is distinct from other nucleic acid approaches. 
Pnt100 is an unmodified phosphodiester Dna sequence 
that is 100 % complementary to its homologous sequence 
of genomic Dna. Our data demonstrate equivalent anti-
tumor activity of mePnt100 and unmethylated Pnt100, 
but no antitumor effects with control scrambled, rando-
mer, or reverse complement sequences. Moreover, in cel-
lular studies, Pnt100’s antiproliferative activity was not 
affected by a methyltransferase inhibitor, suggesting that 
methylation is not required for activity. Virtually identical 
immune response to Pnt2258 and its scrambled control 
in xenografted animals suggests that Pnt100’s sequence 
specificity and not immunogenicity drives BCl-2 modula-
tion and antitumor activity. It is recognized that there are 
limitations to truly defining control sequences for Pnt100. 
as such, there is the possibility that interactions between 
the liposomes and specific oligonucleotide sequences may 
be responsible for the differential effects seen. However, 
if these effects exist, they should be dose dependent and 
should have been observed at doses of 10 mg/kg encap-
sulated oligonucleotide, a dose level that shows antitu-
mor activity for Pnt2258. therefore, by demonstrating, 
the specificity of Pnt100’s pharmacodynamic activity 
using two independent liposomal systems compared to 
empty liposomes, and no effect with encapsulated control 
sequences suggests this is unlikely.
We propose that using unmodified sequences comple-
mentary only to a target gene region may offer advantages. 
the sequence of Pnt100 does not possess toll-like recep-
tor (tlr) immunostimulatory Cpg motifs, a property that 
precludes the need to use chemical modifications to mask 
immune recognition. Further, the observation that Pnt100 
cannot be measured unless the liposomes are disrupted 
suggests fully encapsulated Pnt100 may also contribute 
to immune avoidance. Indeed, no significant changes in 
immune-stimulatory cytokines or clinical signs of anaphy-
laxis observed following dosing of Pnt2258 in patients 
with advanced solid tumors lends support to this approach 
[27]. Clinically, dose-dependent BCl-2-targeted effects 
were observed including reductions in lymphocyte counts 
Fig. 6  continued
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[27]. Pnt2258 was well tolerated in the clinic with doses 
up to 150 mg/m2 (equivalent to ~4 mg/kg).
the lipid composition used for Pnt2258 with its 
amphoteric pH-tunable nature has several distinct fea-
tures. First, the overall particle charge is anionic at blood 
pH which prevents aggregation with blood components and 
eliminates the need for Pegylation. Second, the composi-
tion is sterol rich with CHeMS and MOCHOl, providing 
the cholesterol backbone to anchor the pH responsive head-
group compositions. third, ether linkages often used to 
anchor polyethylene glycol (Peg) or pH responsive head-
groups are not used. Finally, the amphoteric nature enables 
a transition of charge from cationic to net neutral to anionic 
or vice versa depending on the microenvironment [24, 26]. 
For example, during transient acidic ethanolic conditions 
used during formulation, there is an overall positive charge 
to the mixture enabling the efficient encapsulation of the 
negatively charged Pnt100. a shift to pH 7.5 renders an 
overall anionic charge to the particle, repelling unencapsu-
lated oligonucleotide, which is removed during ultrafiltra-
tion. the Pnt2258 drug product typically has a zeta poten-
tial of −40 mV. the anionic surface characteristics and 
unique lipid composition enables stable encapsulation of 
the oligonucleotide, without surface Pnt100, thereby obvi-
ating the need for Peg spacers to prevent aggregation or 
immune recognition. additionally, the anionic nature likely 
alters opsonin adhesion or activation (e.g., complement 
factors) compared with cationic carriers [43]. It may also 
attract exchangeable apolipoproteins such as apoe to facili-
tate cellular uptake through lipoprotein and/or other recep-
tor-mediated uptake pathways [44 and references therein]. 
the novel lipid MOCHOl has been shown to have a pKa 
of approximately 6.5 [26], which is within the range identi-
fied for facilitating endosomal escape [44]. We believe the 
unique features of the lipids and the ratios of the liposomal 
system permits Pnt2258, under the appropriate pHs and 
ionic environments to facilitate endosomal escape, a key 
feature enabling Pnt100 access to nuclei.
Pnt2258 exhibits good systemic exposure follow-
ing intravenous administration and demonstrates antitu-
mor activity against xenografted tumors. Our working 
hypothesis centered on the assumption that BCl-2 expres-
sion is generally low in non-cancerous cells and entry of 
Pnt100 into non-cancerous tissue would not interfere 
with normal homeostasis. Similarly, in tumor types driven 
by BCl-2 transcription, Pnt2258 should demonstrate 
good single-agent activity (compare WSU-DlCl2 with 
Daudi-Burkitt’s), but should potentiate the combination 
drug in tumor types with high BCl-2 expression if BCl-2 
resistance is implicated in disease resistance (e.g., Daudi, 
PC-3, and a375). the key challenge was to achieve suf-
ficient systemic exposure while avoiding dose-limiting 
lipid toxicity. therefore, an overriding goal was to ensure 
that sufficient lipid doses (>100 mg/kg lipid, equivalent to 
4 mg/kg Pnt2258) could be safely administered to ani-
mals to overcome the reticuloendothelial system (reS) 
clearance mechanisms and enable sufficient exposure to 
be efficacious without causing observable toxicities. lipid 
particle numbers are proportional to the nanoparticle diam-
eters [45] and both these parameters greatly influence cir-
culation lifetimes [46], hepatic uptake [47], and impor-
tantly, tolerability and access to extrahepatic tissues in the 
absence of targeting ligands [48, 49]. Moreover, the phar-
macokinetics and tissue access of liposomes are also influ-
enced by surface charge and recognition which are a func-
tion of particle size and composition [46]. liver fenestrae 
and sinusoids across species represent physical barriers of 
~100 nm such that nanoparticles with an average diameter 
size range of ~130 nm will be primarily removed by resi-
dent macrophages and will not readily access hepatocytes, 
which represent the population of liver cells to which lipid 
toxicity is attributed [47]. as a result, the liver is gener-
ally resilient and can tolerate lipid doses of 100 mg/kg or 
greater, depending on the rate of delivery, as evidenced by 
the safety and tolerability of parenteral nutrition contain-
ing daily lipid doses of up to 60 g (administered at 2.5 g/h). 
these factors were taken into account during the develop-
ment of Pnt2258 to ensure that a broad therapeutic win-
dow could be identified. this is evidenced by the relatively 
flat dose response of Pnt2258 above 10 mg/kg (eC50 esti-
mated to be between 3 and 10 mg/kg across the models) 
and tolerability with daily doses of 30 mg/kg (or 750 mg/
kg lipid). We speculate that the unique mixture of lipids 
(that lack ether linkages or Peg) and particle size of the 
amphoteric liposomes contributes to the therapeutic activ-
ity of Pnt2258 in several ways. these include imparting 
stability [24, 26], surface characteristics which prolong cir-
culation times in blood, and permit metabolic breakdown to 
enable repeated dosing. toxicology findings in preclinical 
studies with Pnt2258 showed dose-dependent toxicities 
that were reversible, and attributable to high doses of lipid 
(>300 mg/kg) rather than Pnt100 [27].
Pnt2258 shows broad activity against a variety of tumor 
types with robust single-agent activity in DlBCl where 
BCl-2 transcription drives the genesis and survival of the 
tumors. antitumor activity and long-term survival in com-
bination with docetaxel or rituximab in chemo-resistant 
tumors were also demonstrated. BCl-2 overexpression is 
linked to lower overall survival and adversely influences 
progression-free survival in subtypes of chemotherapy 
naïve nHl patients [50]. after front-line r-CHOP ther-
apy, 30–50 % of these patients fail to respond, with BCl-2 
expression remaining high in patients with germinal center 
DlBCl, suggesting the need for BCl-2-targeted interven-
tions. High-risk patients with revised International Prog-
nostic Index (r-IPI) scores of 3–5 or those with double-hit 
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(BCl-2/MYC positive) phenotypes demonstrate even worse 
prognosis with short survival timelines [51]. Moreover, 
there is a high correlation between BCl-2 expression and 
the presence of the t(14;18) translocation. Our preclinical 
data show that Pnt2258 demonstrates good single-agent 
activity and show additive effect with rituximab in DlBCl 
where the t(14;18) rearrangement exists (WSU-DlCl2) 
and synergistic activity against Daudi-Burkitt’s, suggesting 
that targeting BCl-2 can potentiate other therapies. early 
clinical data indicate antitumor effect in patients whose 
tumors may be BCl-2 dependent [27]. Similarly, combina-
tion with docetaxel results in an additive effect in prostate 
and melanoma models. these results support the rationale 
for combining Pnt2258 with approved agents such as doc-
etaxel and rituximab to potentiate their cytotoxic activity in 
tumor types where BCl-2 plays a role in resistance.
Acknowledgments the authors wish to acknowledge reza 
Sheiknejad and David Olson for screening BCl-2 oligonucleotides 
and Christopher louden for statistical input. We also appreciate the 
critical review of data by Bruce Zetter, anthony tolcher, and Shari 
gaylor. We also thank our collaborators at the nanotechnology Char-
acterization laboratory (nCl) at the nCI for probing physicochemi-
cal characteristics and nanoparticle properties of Pnt100, Pnt2258, 
and controls.
Open Access this article is distributed under the terms of the Crea-
tive Commons attribution license which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. reed JC (1994) Bcl-2 and the regulation of programmed cell 
death. J Cell Biol 124:1–6
 2. Davids MS, letai a (2012) targeting the B-cell lymphoma/leu-
kemia 2 family in cancer. J Clin Oncol 30:3127–3135
 3. Seto M, Jaeger U, Hockett rD, graninger W, Bennett S et al 
(1988) alternative promoters and exons, somatic mutation and 
deregulation of the Bcl-2-Ig fusion gene in lymphoma. eMBO J 
7:123–131
 4. Heckman Ca, Mehew JW, Boxer lM (2002) nF-kappaB acti-
vates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 
21:3898–3908
 5. tsujimoto Y, Bashir MM, givol I, Cossman J, Jaffe e, Croce CM 
(1987) Dna rearrangements in human follicular lymphoma can 
involve the 5′ or the 3′ region of the bcl-2 gene. Proc natl acad 
Sci USa 84:1329–1331
 6. Yonetani n, Ueda C, akasaka t, nishikori M, Uchiyama t, Ohno 
H (2001) Heterogeneous breakpoints on the immunoglobulin 
genes are involved in fusion with the 5′ region of BCl-2 in B-cell 
tumors. J Cancer res 92:933–940
 7. Pickering BF, Yu D, Van Dyke MW (2011) nucleolin protein 
interacts with microprocessor complex to affect biogenesis of 
micrornas 15a and 16. J Biol Chem 286:44095–44103
 8. Iorio MV, Croce CM (2012) Microrna involvement in human 
cancer. eMBO Mol Med 4:143–159
 9. Wilson tr, longley DB, Johnston Pg (2006) Chemoresistance 
in solid tumours. ann Oncol 17:315–324
 10. thomas S, Quinn Ba, Das SK, Dash r, emdad l et al (2013) 
targeting the Bcl-2 family for cancer therapy. exp Opin Cancer 
targets 17:61–75
 11. Blackledge nP, Klose rJ (2011) Cpg island chromatin: a plat-
form for gene regulation. epigenetics 6:147–152
 12. Deaton aM, Bird a (2011) Cpg islands and regulation of tran-
scription. genes Dev 25:1010–1022
 13. thurman re, rynes e, Humbert r, Vierstra H, Maurano Mt 
(2012) the accessible chromatin landscape of the human 
genome. nature 489:75–82
 14. Maston ga et al (2006) transcriptional regulatory elements in 
the human genome. annu rev genomics Hum genet 7:29–59
 15. Sabo PJ, Kuehn MS, thurman r, Johnson Be, Johnson Be et al 
(2006) genome-scale mapping of Dnase I sensitivity in vivo 
using tiling Dna microarrays. nat Methods 3:511–518
 16. Brazda V, laister rC, Jagelska eB, arrowsmith C (2011) Cruci-
form structures are a common Dna feature important for regulat-
ing biological processes. BMC Mol Biol 12:33–48
 17. Kendrick S, Hurley lH (2010) the role of g-quadruplex/i-motif 
secondary structures as cis-acting regulatory elements. Pure appl 
Chem 82(8):1609–1621
 18. Brooks ta, Hurley lH (2010) targeting MYC expression 
through g-Quadruplexes. genes Cancer 1:641–649
 19. Balasubramanian S, Hurley lH, neidle S (2011) targeting 
g-quadruplexes in gene promoters: a novel anticancer strategy? 
nat rev Drug Discov 10:261–275
 20. Young Sl, Korsmeyer SJ (1993) a negative regulatory element 
in the bcl-2 5′-untranslated region inhibits expression from an 
upstream promoter. Mol Cell Biol 13:3686–3697
 21. Chen HM, Boxer lM (1995) P1 binding sites are negative 
regulators of bcl-2 expression in pre-B cells. Mol Cell Biol 
15:3840–3847
 22. Miyashita t, Harigai M, Hanada M, reed JC (1994) Identifica-
tion of a p53-dependent negative response element in the bcl-2 
gene. Cancer res 54:3131–3135
 23. Duan H, Xiang H, Ma l, Boxer lM (2008) Functional long-
range Interactions of the IgH 3′ enhancers with the bcl-2 
Promoter region in t(14;18) lymphoma Cell. Oncogene 
27:6720–6728
 24. Siepi e, lutz S, Meyer S, Panzner S (2011) an ion switch regu-
lates fusion of charged membranes. Biophys J 100:2412–2421
 25. arranz a, reinsch C, Papadakis Ka, Dieckmann a, rauch-
haus U et al (2013) treatment of experimental murine colitis 
with CD40 antisense oligonucleotides delivered in amphoteric 
liposomes. J Control release 165:163–172
 26. andreakos e, rauchhaus U, Stavropoulos a, endert g, Wendisch 
V et al (2009) amphoteric liposomes enable systemic antigen-
presenting cell-directed delivery of CD40 antisense and are thera-
peutically effective in experimental arthritis. arthritis rheum 
60:994–1005
 27. tolcher a, rodrigueza WV, rasco DW et al (2013) a Phase 1 
Study of the BCl2 targeted deoxyribonucleic acid inhibitor 
(Dnai) Pnt2258 in patients with advanced solid tumors. Cancer 
Chemother Pharmacol 2013 (in press)
 28. Wagner a, Vorauer-Uhl K, Kreismayr g, Katinger H (2002) the 
crossflow injection technique—an improvement of the ethanol 
injection method. J liposome res 12(3):259–270
 29. Wagner a, Vorauer-Uhl K, Katinger H (2002) liposome pro-
duced in a pilot scale: production, purification and efficiency 
aspects. eur J Pharm Biopharm 54:213–219
 30. Corbett tH, roberts BJ, leopold Wr, Peckman JC, Wilkoff lJ 
et al (1984) Induction and Chemotherapeutic response of two 
transplantable Ductal adenocarcinomas of the Pancreas in 
C57Bl/6 Mice. Cancer res 44:717–726
 31. Mohammad rM, Mohamed an, Smith Mr, Jawadi n, al-
Katib a (1993) a unique eBV- negative low-grade lymphoma 
166 Cancer Chemother Pharmacol (2014) 74:151–166
1 3
line (WSU-FSCCl) exhibiting both t(14;8) and t(8;11). Cancer 
genetics Cytogenetics 70:62–67
 32. Dias n, Stein C (2002) antisense oligonucleotides: basic con-
cepts and mechanisms. Mol Cancer ther 1:347–355
 33. Kawasaki H, taira K (2004) Induction of Dna methylation and 
gene silencing by short interfering rnas in human cells. nature 
431:211–217
 34. rudin CM, Marshall Jl, Huang CH, Kindler Hl, Zhang C et al 
(2004) Delivery of a liposomal c-raf-1 antisense oligonucleotide 
by weekly bolus dosing in patients with advanced solid tumors: a 
phase I study. Clin Cancer res 10:7244–7251
 35. Fahy Bn, Schlieman Mg, Mortenson MM, Virudachalam S, Bold 
rJ (2005) targeting BCl-2 overexpression in various human 
malignancies through nF-kappaB inhibition by the proteasome 
inhibitor bortezomib. Cancer Chemother Pharmacol 56:46–54
 36. gabizon a, tzemach D, Mak l, Bronstein M, Horowitz at 
(2002) Dose dependency of pharmacokinetics and therapeutic 
efficacy of pegylated liposomal doxorubicin (DOXIl) in Murine 
Models. J Drug target 10:539–548
 37. Sullivan gF, amenta PS, Villanueva JD, alvarez CJ, Yang JM, 
Hait Wn (1998) the expression of drug resistance gene products 
during the progression of human prostate cancer. Clin Cancer res 
4:1393–1403
 38. Janowski Ba, Huffman Ke, Schwartz JC, ram r, Hardy D et al 
(2005) Inhibiting gene expression at transcription start sites 
in chromosomal Dna with antigene rnas. nat Chem Biol 
1:216–222
 39. liu CM, lui DP, liang CC (2002) Oligonucleotide-mediated 
gene repair at Dna level: the potential applications for gene ther-
apy. J Mol Med 80:620–628
 40. Kole r, Krainer ar, altman S (2012) rna therapeutics: beyond 
rna interference and antisense oligonucleotides. nat rev Drug 
Discovery 11:125–140
 41. Vaishnaw aK, gollob J, gamba-Vitalo C, Hutabarat r, Sah D 
et al (2010) review: status report on rnai therapeutics. Silence 
1:14–26
 42. Deleavey gF, Damha MJ (2012) Designing chemically modi-
fied oligonucleotides for targeted gene silencing. Chem Biol 
19:937–954
 43. Chonn a, Cullis Pr, Devine DV (1991) the role of surface 
charge in the activation of the classical and alternative pathways 
of complement by liposomes. J Immunol 146:4234–4241
 44. akinc a, Querbes W, De S, Qin J, Frank-Kamenetsky M et al 
(2010) targeted Delivery of rnai therapeutics With endog-
enous and exogenous ligand-Based Mechanisms. Mol ther 
18:1357–1364
 45. Hope MJ, rodrigueza WV (1995) Membrane lipids and model 
membrane systems. In: Severs n, Shotton D (eds) rapid freezing, 
freeze fracture and deep etching (techniques in modern biomedi-
cal microscopy). Wiley, new York, pp 235–253
 46. rodrigueza WV, Pritchard PH, Hope MJ (1993) Influence of 
size and composition on the cholesterol mobilizing properties of 
liposomes in vivo. Biochim Biophys acta 1153:9–19
 47. rodrigueza WV, Mazany Ke, essenburg ae, Pape Me, Bisgaier 
Cl, Williams K (1997) large versus small unilamellar vesicles 
mediate reverse cholesterol transport in vivo into two distinct 
hepatic metabolic pools: implications for the treatment of athero-
sclerosis. arterioscler thromb Vasc Biol 17:2132–2139
 48. Farokhzad OC, langer r (2009) Impact of nanotechnology on 
drug delivery. aCS nano 3(1):16–20
 49. Maurer n, Fenske DB, Cullis Pr (2001) Developments in liposo-
mal drug delivery systems. expert Opin Biol ther 1(6):923–947
 50. Iqbal J, Meyer Pn, Smith lM, Johnson na, Vose JM et al (2011) 
BCl-2 Predicts Survival in germinal Center B-cell-like DlBCl 
treated with CHOP-like therapy and rituximab. Clin Cancer 
res 17:7785–7795
 51. green tM, Young KH, Visco C, Xu-Monette ZY, Orazi a (2012) 
Immunohistochemical Double Hit Score is a Strong Predictor 
of Outcome in Patients with Diffuse large B-Cell lymphoma 
treated with rituximab Plus Cyclophsphamide, Doxorubicin, 
Vincristine, and Prednisone. J Clin Oncol 30:3460–3467
